Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Recruiting · NCT07089186 · Registry updated 2025-07-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections | Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome | Recruiting | Phase 3 | 2025-07-30 | NCT07089186 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Qilu Pharmaceutical Co., Ltd. | 126 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Huashan Hospital, Fudan Universit | Shanghai | China | 1 |